CD8A and neoplasm: To confirm if the vaccinated mice develop tumor‐specific immunity against GL261 tumor cells, we quantified GL261 tumor antigen‐specific CD8+ T cells in two old rGL261‐MBTA mice that achieved CR and two age‐matched wild‐type mice.